Atlas Trials

Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

Clinical trial NCT05440942 · COMPLETED

Trial details

NCT number
NCT05440942
Sponsor
Peter Hosein, MD
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Pancreatic Ductal Adenocarcinoma
Start date
2023-01-19
Primary completion
2025-05-30
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.